CLINICAL ROLE -
Ryan Haumschild, PharmD, MS, MBA, leads a panel of experts in a discussion surrounding updates in CDK4/6 inhibitor use for patients with HR+/HER2- metastatic breast cancer.
EP. 1: Impact of Metastatic Breast Cancer on Quality of Life
A panel of medical experts begin a discussion surrounding key updates in treatment and management of HR+/HER2- metastatic breast cancer.
EP. 2: Emergence of CDK4/6 Inhibitors in mBC Treatment Pathway
Ryan Haumschild, PharmD, MS, MBA, leads drives a conversation surrounding the impact of CDK4/6 inhibitors in treatment of metastatic breast cancer.
EP. 3: Hormone Therapy in Patients with HR+/HER2- Metastatic Breast Cancer
Hormone therapy in metastatic breast cancer management is examined by key opinion leaders.
EP. 4: Role of the Pharmacist in Managing Side Effects Associated With CDK4/6 Therapy
Heather Moore, CPP, PharmD, BCOP, highlights the impact of pharmacists in adverse effect profile management for CDK4/6 inhibitors.
EP. 5: Ensuring Patient Adherence to CDK4/6 Therapy
Rose DiMarco, PharmD, BCPS, BCOP, addresses strategies to maximize patient adherence to CDK4/6 inhibitor therapy.
EP. 6: Navigating Treatment Failure in CDK4/6 Therapy From The Pharmacist’s Perspective
The pharmacist’s role in addressing treatment failure for patients receiving CDK4/6 inhibitors is examined.
EP. 7: Progression-Free Survival and Overall Survival Associated With CDK4/6 Inhibitor Therapy
Expert panelists discuss the impact of CDK4/6 inhibitor therapy on progression-free and overall survival.
EP. 8: SONIA Trial Findings Driving Implementation of CDK4/6 Inhibitors in mBC Treatment Paradigm
Jacob Kettle, PharmD, BCOP, joins Drs Haumschild and DiMarco in a conversation surrounding findings from the SONIA trial and their impact on shifting mBC treatment strategies.
EP. 9: Differentiating Between Adverse Event Profiles of Various CDK4/6 Inhibitors
Adverse event profiles of several approved CDK4/6 inhibitors are discussed.
EP. 10: NCCN Guidelines on CDK4/6 Inhibitor Treatment Regimens
Dr Kettle outlines NCCN guideline-directed therapy surrounding CDK4/6 inhibitors.
EP. 11: mBC Treatment Optimized Through Shared Decision-Making Process
Medical experts weigh in on the strength of collaborative care and shared decision-making in the management of metastatic breast cancer (mBC).
EP. 12: Navigating Social Determinants of Health Impacting Patients with mBC
Social determinants of health create a myriad of obstacles to optimal care for patients receiving treatment for metastatic breast cancer.
EP. 13: Navigating Medication Therapy Management in mBC Treatment
Medical experts weigh in on key points of emphasis surrounding medication therapy management for patients diagnosed with mBC
EP. 14: Evaluating Clinical Pathways in mBC Treatment
Drs DiMarco and Moore weigh the benefits and barriers associated with clinical pathways in treating patients with mBC.
EP. 15: Unmet Needs in mBC Treatment Landscape
Dr Kettle provide insights into unmet needs surrounding treatment of metastatic breast cancer.
EP. 16: Key Points of Emphasis Surrounding CDK4/6 Inhibitor in mBC Treatment
With their final thoughts, the panelists provide key takeaways from their conversation regarding CDK4/6 inhibitor therapy in treatment of HR+/HER2- metastatic breast cancer.
2 Clarke Drive Cranbury, NJ 08512